Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalPsychiatryPTSDTrial Update

Study on Predictors of PTSD Relapse in Children and Families

This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies.

Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / PTSD
Asset: Study
Trial SummaryCLN

Phase III

Psychiatry / PTSD

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies.

Why it matters

This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies.

What changed

Trial Update

Analysis

This study aims to identify clinical and neuropsychological markers that may predict PTSD relapse in children and their families.

This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies.

Monitor results for potential biomarkers that could be leveraged in future PTSD treatment protocols.

Related companies & assets

Assets

  • Study →
  • mental health therapy companies →

Sources & Humanexa intelligence

Source links

  • Study on Predictors of PTSD Relapse in Children and Families ↗

Related Humanexa pages

  • Study on Predictors of PTSD Relapse in Children and Families →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.